Stoke Therapeutics, Inc. (STOK) saw its stock price soar 5.39% during intraday trading on Friday.
The surge follows a significant analyst action, as Canaccord Genuity raised its price target for the company to $60 from $36, representing a substantial vote of confidence in the biotech firm's outlook.
Broader Wall Street optimism was also noted, with multiple analysts recently expressing bullish views on Stoke Therapeutics among other healthcare picks.